Upstream Bio (UPB) Cash from Financing Activities (2023 - 2026)
Upstream Bio (UPB) posted quarterly Cash from Financing Activities of $598000.0 for Q1 2026, up 1858.82% year-over-year from $30528.5 in Q1 2025, and down 45.78% quarter-over-quarter from $1.1 million in Q4 2025.
Upstream Bio (UPB) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Upstream Bio's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $598000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 1858.82% year-over-year to $598000.0; the TTM figure through Mar 2026 stood at $3.1 million (down 99.25% YoY), while the FY2025 annual figure was $2.4 million, down 99.42% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $598000.0, down from $1.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $270.6 million in Q4 2024, with the low at -$1.6 million in Q3 2024.
- The 4-year median for Cash from Financing Activities is $686000.0 (2025), against an average of $42.2 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 203594.74% in 2024, then sank 100.36% in 2025.
- Upstream Bio's Cash from Financing Activities stood at -$133000.0 in 2023, then soared by 203594.74% to $270.6 million in 2024, then slumped by 99.59% to $1.1 million in 2025, then plunged by 45.78% to $598000.0 in 2026.
- Business Quant data shows UPB's Cash from Financing Activities at $598000.0 in Q1 2026, $1.1 million in Q4 2025, and $760000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 2.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.53 Mn |
| Jun 30, 2026 | 2.53 Mn |
| Mar 31, 2026 | 598,000.00 |
| Mar 31, 2026 | 598,000.00 |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 760,000.00 |
| Sep 30, 2025 | 760,000.00 |
| Jun 30, 2025 | 612,000.00 |
| Jun 30, 2025 | 612,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Dec 31, 2024 | 270.65 Mn |
| Dec 31, 2024 | 270.65 Mn |
| Sep 30, 2024 | -1.64 Mn |
| Sep 30, 2024 | -1.64 Mn |
| Jun 30, 2024 | 140.52 Mn |
| Jun 30, 2024 | 140.52 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Mar 31, 2024 | 9.39 Mn |